aBLA Filing Intelligence & Biosimilar Opportunity

Columvi

Glofitamab-Gxbm

Anticancer

IV Injection

Columvi is an antibody-based therapy for adults with relapsed or refractory diffuse large B-cell lymphoma. It activates the immune system to target and destroy cancer cells when other treatments have failed.

Approval Date

15-Jun-23

Data Exclusivity Expiry

15-Jun-27

Market Exclusivity Expiry

15-Jun-35

Commercial snapshot

Market performance & projections

Revenue ($M)

347

CAGR (%)

38.94%

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

541

2027

738

2028

1,018

2029

1,293

2030

1,546

2031

1,789

2032

2,022

Molecule profile

Details & specifications

Molecule

Glofitamab-Gxbm

Innovator

ROCHE

Dosage Form

IV Injection

Strength

2.5 mg/2.5 mL and 10 mg/10 mL

Therapeutic Category

Anticancer

Usage

To treat diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after two or more lines of systemic therapy

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets